MindRank’s oral GLP-1 is the furthest along any AI-native drug programme

MDR-001, MindRank’s oral GLP-1 receptor agonist for obesity and diabetes, entered Phase III after four and a half years and $23 million in research. The Molecule Arts platform, which merges biological, chemical, computational and clinical data, enabled the rapid progression. MindRank closed a $52 million Series B in July, holds three IND clearances in China and the US, and is developing five additional preclinical candidates.